Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study

• DOI: 10.1111/bjh.12765
• Publication Date: 2014-02-07T11:36:45Z
• Authors: Andre Wieringa; Karin Boslooper; Mels Hoogendoorn; Peter Joosten; Tim Beerden; Huib Storm; Robby E. Kibbelaar; Gerrit J. Veldhuis; Harmen van Kamp; Bastiaan van Rees; Hanneke C. Kluin-...; Nic J. G. M. Veeger; Eric N. van Roon
• Keywords: International Prognostic Index

An observational population-based cohort study was performed to investigate the role of comorbidity on outcome and treatment-related toxicity in patients with newly diagnosed advanced-stage diffuse large B-cell lymphoma (DLBCL) treated R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Data for clinical characteristics 154 (median age 69 years), including Charlson Comorbidity Index (CCI), treatment, were evaluated. Forty-five percent had an International Prognistic index ≥3 16% a CCI ≥2. The planned schedule completed by 84% 75% reached complete remission (CR). In those ≥2, 67% treatment 46% CR. <2, overall survival (OS) after 1, 2 5 years 84%, 79% 65% respectively it 64%, 48% Grade III/IV documented 53%, most frequently febrile neutropenia (27%) infections (23%). multivariate analysis ≥2 IPI independent risk indicators OS grade toxicity. conclusion, is indicator worse advanced DLBCL interference intensive schedules more Future studies are warranted determine optimal approach significant comorbidities.